Kancera Future Growth

Future criteria checks 3/6

Kancera is forecast to grow earnings and revenue by 88.9% and 149.8% per annum respectively while EPS is expected to grow by 95.1% per annum.

Key information

88.9%

Earnings growth rate

95.1%

EPS growth rate

Biotechs earnings growth	38.9%
Revenue growth rate	149.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OM:KAN - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	69	54	N/A	54	1
12/31/2024	N/A	-81	N/A	-87	1
12/31/2023	N/A	-65	-56	-56	N/A
9/30/2023	N/A	-60	-52	-52	N/A
6/30/2023	N/A	-61	-58	-58	N/A
3/31/2023	N/A	-58	-57	-57	N/A
12/31/2022	N/A	-52	-48	-48	N/A
9/30/2022	N/A	-51	-53	-53	N/A
6/30/2022	N/A	-52	-50	-50	N/A
3/31/2022	N/A	-49	-44	-44	N/A
12/31/2021	N/A	-46	-44	-44	N/A
9/30/2021	N/A	-45	-41	-41	N/A
6/30/2021	0	-44	-39	-39	N/A
3/31/2021	0	-38	-39	-39	N/A
12/31/2020	0	-40	-39	-39	N/A
9/30/2020	0	-35	-29	-29	N/A
6/30/2020	0	-34	-29	-29	N/A
3/31/2020	0	-40	-36	-36	N/A
12/31/2019	3	-36	-33	-33	N/A
9/30/2019	4	-41	-46	-46	N/A
6/30/2019	3	-44	-53	-53	N/A
3/31/2019	3	-41	-41	-41	N/A
12/31/2018	0	-46	-45	-45	N/A
9/30/2018	0	-46	-50	-50	N/A
6/30/2018	0	-52	-41	-41	N/A
3/31/2018	0	-59	-54	-54	N/A
12/31/2017	0	-56	-54	-54	N/A
9/30/2017	0	-51	N/A	-41	N/A
6/30/2017	0	-39	N/A	-40	N/A
3/31/2017	0	-27	N/A	-26	N/A
12/31/2016	0	-22	N/A	-23	N/A
9/30/2016	0	-22	N/A	-22	N/A
6/30/2016	0	-20	N/A	-19	N/A
3/31/2016	0	-20	N/A	-22	N/A
12/31/2015	0	-20	N/A	-21	N/A
9/30/2015	0	-19	N/A	-24	N/A
6/30/2015	0	-18	N/A	-23	N/A
3/31/2015	0	-17	N/A	-21	N/A
12/31/2014	0	-16	N/A	-19	N/A
9/30/2014	2	-13	N/A	-9	N/A
6/30/2014	2	-13	N/A	-9	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-7	N/A	-7	N/A
9/30/2013	2	-16	N/A	-13	N/A
6/30/2013	3	-20	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KAN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: KAN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: KAN is expected to become profitable in the next 3 years.

Revenue vs Market: KAN is forecast to have no revenue next year.

High Growth Revenue: KAN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KAN's Return on Equity is forecast to be high in 3 years time

Kancera Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Recent updates

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies